A study for people looking to transition from Buprenorphine maintenance to VIVITROL

Site Image

Study Overview

Up to 9 weeks, including Screening (up to 3 weeks), up to 2 weeks for Lead-in Period and residential Treatment Period receiving decreasing doses of Buprenorphine and increasing doses of either active or placebo Naltrexone, 4-5 days for VIVITROL induction and post-VIVITROL monitoring, and a 4-week outpatient follow-up period.

  • Study Identifier: 825716

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu